Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.36-0.57 (-2.29%)
At close: 04:00PM EDT
23.85 -0.51 (-2.09%)
After hours: 04:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.93
Open24.90
Bid22.16 x 1800
Ask23.85 x 1100
Day's Range23.26 - 25.13
52 Week Range18.21 - 58.00
Volume741,451
Avg. Volume1,706,071
Market Cap3.188B
Beta (5Y Monthly)-0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est53.29
  • GlobeNewswire

    Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details

    SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20, 2022, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of record as of March 28, 2022 (the “Record Date”) can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/VIR2

  • Zacks

    AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

    AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.

  • Benzinga

    HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

    Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ: VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline, which includes compounds in development for chronic hepatitis B virus (CHB), human immunodeficiency viru

Advertisement
Advertisement